Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
April 23, 2019Thoracic CancerOpen Access

Molecular characterization of clinical responses to PD‐1/PD‐L1 inhibitors in non‐small cell lung cancer: Predictive value of multidimensional immunomarker detection for the efficacy of PD‐1 inhibitors in Chinese patients

View Full Paper
Ask AI
Bookmark
Share

Authors

PSPeng SongXCXiaoxia CuiLBLi Bai

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Song et al. (2019) studied this question.

synapsesocial.com/papers/6a1069fb8090e499da611fdfhttps://doi.org/10.1111/1759-7714.13078
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)2011 · 1,612 citations
  2. 2Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors2017 · 5,687 citations
  3. 3Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma2009 · 8,320 citations
  4. 4Proliferative potential and resistance to immune checkpoint blockade in lung cancer patients2019 · 108 citations
  5. 5Hyperprogressors after Immunotherapy: Analysis of Genomic Alterations Associated with Accelerated Growth Rate2017 · 863 citations